Emtricitabin, Tenofovir-alafenamid, Elvitegravir a Kobicistat
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| 1383/2022-SML | 19. 08. 2022 | Gilead Sciences s.r.o. | 28 420 095,44 | 25 836 450,40 | 28 420 095,44 | 25 836 450,40 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| Písemná zpráva zadavatele_Emtricitabin, Tenofovir-alafenamid, Elvitegravir a Kobicistat_EP.pdf | Písemná zpráva zadavatele | 29. 08. 2022 10:20 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| Gilead Sciences s.r.o. | Praha | 28 420 095,44 | 25 836 450,40 | CZK |
Price Actually Paid in Each Year of Performance
| 1383/2022-SML | 2023 | 4 304 807,64 | 3 913 462,50 |
| 1383/2022-SML | 2022 | 1 253 827,56 | 1 139 843,24 |